PASSAGE BIO ANNOUNCES PROMISING INTERIM CLINICAL DATA FROM FIRST EIGHT PATIENTS WITH GM1 GANGLIOSIDOSIS IN IMAGINE-1 STUDY Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profile Dose 2...
Abcuro Announces $155 Million Oversubscribed Series B Financing to Further Advance Autoimmune Pipeline Financing co-led by Redmile Group and Bain Capital Life Sciences Proceeds to support completion of Phase 2/3 registrational trial of ABC008, a first-in-class...
Edgewise Therapeutics Announces Positive 12-Month Topline Results From The ARCH Open Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy (BMD) – Sustained positive trend in North Star Ambulatory Assessment (NSAA) scores relative to BMD natural history – –...
Vega Therapeutics Receives FDA Orphan Drug Designation for VGA039 for the Treatment of von Willebrand Disease SOUTH SAN FRANCISCO, CA, May 23, 2023 – Vega Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for rare blood disorders,...
HARPOON THERAPEUTICS ANNOUNCES COMPLETION OF PLANNED PATIENT ENROLLMENT IN PHASE 1 STUDY OF HPN217 IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SOUTH SAN FRANCISCO, Calif., June 27, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage...
Silver Cross Hospital Expands Use of Kyruus’ Award-Winning Online Scheduling Solution Across Specialties and Services 348-Bed Community Hospital Builds on Success of Preventive and Diagnostic Care Scheduling Impact Boston, MA – June 20, 2023 – Kyruus, the leader in...
Recent Comments